This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Amgen Presents Nearly Two Dozen Abstracts From Romosozumab And Prolia® (Denosumab) At ASBMR

THOUSAND OAKS, Calif., Oct. 4, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present data from several romosozumab and Prolia ® (denosumab) studies at the American Society for Bone and Mineral Research (ASBMR) 2013 Annual Meeting in Baltimore from Oct. 4-7, 2013.

Romosozumab data include results from the Phase 2 study that demonstrate significant increases in volumetric bone mineral density. Romosozumab is being developed in collaboration with UCB. Prolia data include 19 abstracts, featuring several on long-term safety and efficacy data from the open-label extension study of the pivotal Phase 3 fracture trial for up to eight years.

"We are very encouraged by the long-term safety and efficacy data with Prolia treatment as well as by the clinical data we see from our pipeline bone-building molecule, romosozumab," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "Amgen has led nearly a decade of clinical work in bone biology and, with fracture rates on the rise, we remain committed to advancing medicines that help treat bone disease."

SELECTED ABSTRACTS OF INTEREST INCLUDE:Abstracts are available on the ASBMR website at and updated data will be presented at the meeting.

Prolia Abstracts of Interest:
  • Eight Years of Denosumab Treatment in Postmenopausal Women With Osteoporosis: Results From the First Five Years of the FREEDOM Extension   Abstract LB-MO26, Late Breaking Abstract Session, Monday, Oct. 7, 10:35 – 10:40 a.m. EDT (Discovery Hall-Hall C)
  • Denosumab Significantly Increases Bone Mineral Density Compared With Ibandronate and Risedronate in Postmenopausal Women Previously Treated With an Oral Bisphosphonate Who are at Higher Risk for Fracture Abstract 1018, Oral Presentation, Saturday, Oct. 5, 8:15 – 8:30 a.m. EDT (Hall A)
  • Further Reduction in Nonvertebral Fracture Rate Is Observed Following Three Years of Denosumab Treatment: Results With Up to Seven Years in the FREEDOM ExtensionAbstract 1017, Oral Presentation, Saturday, Oct. 5, 8:00 – 8:15 a.m. EDT (Hall A)

Romosozumab Abstract of Interest:
  • Effect of Romosozumab on Lumbar Spine and Hip Volumetric Bone Mineral Density (vBMD) as Assessed by Quantitative Computed Tomography (QCT) Study 20060326, Oral Presentation, Saturday, Oct. 5, 9:15 – 9:30 a.m. EDT (Hall A)

1 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,776.43 +304.06 1.85%
S&P 500 1,987.05 +35.69 1.83%
NASDAQ 4,781.2640 +73.4890 1.56%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs